KRAS and familial pancreatic carcinoma: K-Ras mutations are present in approximately 95% of pancreatic cancers, leading to burst activation of the mitogen-activated protein kinase (MAPK) pathway, also known as the Ras-Raf-MEK-ERK pathway [3].